Annals of Hepatology

Article	Citations
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	517
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	143
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	66
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	65
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	54
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	49
Comment on “burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990–2021: Results from the global burden of disease study, 2021”	46
P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	46
CRITICAL MEDIATORS OF INFLAMMATION-DRIVEN HEPATOCARCINOGENESIS INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	44
THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ADULT SUBJECTS WITH COMPENSATED LIVER CIRRHOSIS AND BACTERIAL OVERGROWTH	44
IMPROVEMENT OF CARDIOVASCULAR RISK ASSESSMENT ON A COHORT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)	39
PLANT-DERIVED MONOTERPENE SYNERGIZES WITH SORAFENIB TO SUPPRESS DRUG-TRIGGERED HEPATOCELLULAR CARCINOMA IN ANIMALS	39
INFLUENCE OF GLYCEMIC CONTROL ON THE SEVERITY OF HEPATIC STEATOLOGY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	38
AUTOIMMUNE HEPATITIS IN LATIN AMERICA: INSIGHTS FROM THE ALLATIN COHORT	38
Skeletal muscle as a source of IGFBP-2 in a murine model of metabolic dysfunction associated with steatotic liver disease.	38
Acute Liver Failure due to Hepatitis A Virus: A Report of Two Cases	36
Neutrophil/lymphocyte index as a prognostic predictor in patients with primary biliary cholangitis	33
Characterization and determination of prevalence in autoimmune liver diseases in a tertiary center.	32
Kasabach-Merritt syndrome in an adult treated by embolization prior to liver transplantation: a case report.	31
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	30
Examining genetic associations with hepatic steatosis in Mexican-origin adults	28
Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	28
Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	28
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	27
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	27

Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	26
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	26
A thorny matter: Spur cell anemia	26
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	24
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	24
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	23
Challenges and adherence to hepatocellular carcinoma surveillance in patients with advanced chronic liver disease	22
A practical approach to the endoscopic management of biliary strictures after liver transplantation	22
Energy metabolism: An emerging therapeutic frontier in liver fibrosis	22
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	21
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	21
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	20
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	20
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045	20
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	20
P-106 DIAGNOSTIC ACCURACY OF SHEAR-WAVE ELASTOGRAPHY IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE, A SINGLE CENTER REPORT	20
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	20
P-40 ASSOCIATION BETWEEN LIVER STIFFNESS MEASUREMENTS USING MR ELASTOGRAPHY AND PORTOSYSTEMIC SHUNTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE	20
DILI and Dress syndrome secondary to treatment with DoTbal, in a patient with tuberculosis at the rural hospital from Papantla – IMSS Bienestar	19
P-65 NEOPORTA WITH OR WITHOUT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A VIABLE TREATMENT OF CHRONIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS	19
Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis	19
P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION	19
TSH and its Correlation in the Development of Fibrosis in Patients with Hypothyroidism in a Tertiary Care Hospital	18
Impact of neohepatic albumin-bilirubin scores on renal outcomes following living donor liver transplantation: a propensity score analysis	18
Liver Injury Induced by Peumus boldus with Fatal Outcome. Case Report	17
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients	17
Ceftriaxone versus cefotaxime in the treatment of spontaneous bacterial peritonitis	17
The Hepatic Effect of Sub-chronic Chronic Cadmium Exposure.	17
Regression of fibrosis and portal hypertension in chronic liver disease: Endothelial perspectives and clinical implications	16
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis	16
Autoimmune hepatitis with superimposition of primary sclerosing cholangitis on non-specific chronic ulcerative colitis	15
OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY	15
P-15 MMP-2 AND MMP-9 LEVELS IN ALCOHOLIC LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC HEPATITIS C	14
P-2 DE NOVO LIPOGENESIS MARKERS ARE INVOLVED IN METABOLIC ASSOCIATED FATTY LIVER DISEASE PROGRESSION IN BTBR OB/OB MICE	14
Trajectories of patients relisted for liver transplantation	14
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease	14
Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model	14
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA	13
Treatment with nucleoside and nucleotide analogues in patients with chronic hepatitis B virus infection	13
Detection of Hepatitis C and risk factors in the general population of the Centro Médico Nacional La Raza	13
P-13 PREVALENCE, CHARACTERIZATION, AND SURVIVAL OF ACUTE ON CHRONIC LIVER FAILURE IN A LATIN AMERICAN COHORT:  A MULTICENTER STUDY	13
P-123 HEPATOCELLULAR CARCINOMA SURVIVAL: EXPERIENCE OF THE MULTIDISCIPLINARY COMMITTEE AT HOSPITAL ESPECIALIDADES EUGENIO ESPEJO IN QUITO – ECUADOR	13
P- 26 EFFECT OF PROTEIN X OF THE HEPATITIS B VIRUS AND HEXACHLOROBENZENE ON LIVER CELL GROWTH DYSREGULATION	13
PROGNOSTIC VALUE OF AST/ALT AND GGT/ALP RATIOS IN PATIENTS WITH CHOLANGIOCARCINOMA	12
The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis	12
LIPOUNITS: A NOVEL UNIT OF MEASUREMENT TO COMMUNICATE THE IMPACT OF DAILY HABITS ON LIVER FAT IN PATIENTS WITH MASLD	12
DRUG-INDUCED DUCTOPENIA IN THE SPANISH AND LATINDILI REGISTRIES	12
HEPATITIS C SCREENING AND GENDER DISPARITIES IN POSITIVITY RATES IN ARGENTINA	12
NURSING CARE STRATEGIES FOR INDIVIDUALS WITH VIRAL HEPATITIS IN THE CONTEXT OF PRIMARY HEALTH CARE	12
CLINICAL RESULTS IN PATIENTS WITH GASTROESOPHAGEAL VARICEAL BLEEDING IN THE ICU: ANALYSIS OF 85 CASES IN A TERTIARY CARE CENTRE	12

INCIDENCE AND PREDICTORS OF POST-TRANSPLANT MALIGNANCY IN LIVER TRANSPLANT RECIPIENTS: A SINGLE-CENTRE COHORT STUDY	12
Trends of metabolic dysfunction-associated steatotic liver disease in Mexico, 1990–2023: insights from the Global Burden of Disease Study	12
Comment on “Pancreatic involvement and its prognostic impact in acute-on-chronic liver failure”	11
Learning is not enough: enhancing the reach and rigor of hepatitis eLearning	11
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	11
Data mining reveals novel gene drivers of lenvatinib resistance in hepatocellular carcinoma	11
Predictors of recompensation in immunosuppressive therapy for biopsy-proven autoimmune hepatitis patients with decompensated cirrhosis	11
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease	10
Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma	10
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	10
P-4 RISK OF HCC IN SOUTH AMERICANS ASSOCIATED WITH TLL1 VARIANT SINGLE NUCLEOTIDE POLYMORPHISM	10
Evaluation of the MELNa AGIB Scale to Predict Mortality in Patients with Cirrhosis and Variceal Hemorrhage.	10
Epidemiology and natural history of chronic Hepatitis B in the Canadian province of Alberta from 2012 to 2021: A population-based study	10
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy	10
P- 18 ANASTROZOLE MAY NOT BE ASSOCIATED FATTY LIVER DISEASE AND HEPATIC FIBROSIS IN WOMEN WITH BREAST CANCER	10
P- 107 EPIDEMIOLOGY, CLINICAL AND TISSUE CHARACTERISTICS OF A LARGE COHORT OF NAFLD/NASH FROM SOUTH AMERICA	9
Role of tamsulosin in recovery from thioacetamide-induced subchronic liver damage in a Wistar rat model	9
PROGNOSTIC ABILITY OF DIFFERENT SCORING SYSTEMS TO PREDICT VERY EARLY MORTALITY IN PATIENTS WITH CIRRHOSIS AND ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)	9
MRI Imaging and Machine Learning Based Radiomics for Detection of Mixed HCC and CCA Tumors	9
NON-INVASIVE ASSESSMENT OF STEATOHEPATITIS AND LIVER FIBROSIS IN THE POPULATION AT RISK FOR METABOLIC STEATOTIC LIVER DISEASE	9
Clues to decipher the origin of severe acute hepatitis in children: a new enigma during the COVID-19 pandemic	9
Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico	9
FUELING THE FIRE: INFECTIONS TRIGGER AND MALNUTRITION DRIVES SEVERE ACLF IN CIRRHOSIS	9
Hepatic histologic findings in a murine model of diet induced-steatotic liver disease and acute alcohol intake	9
Stroop test, Quickstroop, and the 1-min animal naming test for minimal hepatic encephalopathy diagnosis: A multicenter study in Mexico	9
Jejunal lymphoma of large cell high grade B monomorphic in a patient with hepatic transplant	9
Evaluation of the early response to empirical treatment and its association with cultures in patients with spontaneous bacterial peritonitis (SBP)	9
P-41 MICRORNAs FROM EVs AS POTENTIAL LIVER FIBROSIS NON-INVASIVE BIOMARKERS IN CHRONIC HEPATITIS C	9
Serum Immunoglobulin M levels and neutrophil/lymphocyte index as predictors of treatment response in patients with primary biliary cholangitis	9
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany	8
Autoimmune hemolytic anemia as a paraneoplastic syndrome in hepatocarcinoma, case report	8
Endohepatology: current status and perspectives	8
Prevalence of liver cirrhosis based on the metabolic health and weight criteria: Report from the Korea National Health and Nutrition Examination Survey (KNHANES) data analysis	8
P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MA	8
OP-1 FEATURES OF IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN LATIN AMERICA: LONG-TERM EXPERIENCE OF THE LATINDILI NETWORK	8
Regulation of TGF-β1, 2, and 3 and IL-10 at systemic level in chronic liver disease	8
Editorial board	8
Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023	8
Involvement of the hedgehog signaling pathway in liver diseases	8
P-44 LONG-TERM SURVIVAL IN PATIENTS WITH LIVER TRANSPLANTATION	8
O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA	8
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease	8
EDITORIAL BOARD	8
IL-18 discriminates highly frequent hepatitis E virus positive from negative blood donors in Mexico	8
MAFLD vs. MASLD: Consensus is unlike evidence!	8
O-11 THE PUBLIC HEALTH POLICIES REDUCE THE LONG-TERM BURDEN OF ALCOHOL-ASSOCIATED LIVER DISEASE WORLDWIDE: DEVELOPMENT OF A PREPAREDNESS INDEX	7
LONG-TERM ALBUMIN THERAPY MAY IMPROVE SURVIVAL IN CIRRHOSIS WITH ASCITES: A SYSTEMATIC REVIEW AND META-ANALYSIS	7
Radiofrequency ablation and percutaneous ethanol injection versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis	7
P-14 SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: PREVALENCE AND ANTIBIOTIC RESISTANCE PATTERNS	7
Demographic and clinical characteristics of MASLD and Met-ALD patients: Insights from NHANES 2017–2020	7
Outcomes and risk of relapse after living donor and deceased donor liver transplantation for alcohol-associated liver disease	7
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation	7
Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina	7
Comment on “Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease”	7
Differential effect of the allele G ADRB2 (rs1042714) and allele C ADRB3 (rs4994) and its association with metabolic-associated steatotic liver disease (MASLD) risk factors in Mexican population.	7
CLINICAL CHARACTERIZATION OF HCC IN A SILENT REGION: REAL-WORLD DATA FROM A PROSPECTIVE COHORT IN CENTRAL AMERICA	7
WHAT IS THE PROGNOSTIC VALUE OF A BLOOD TEST COUNT IN PATIENTS WITH ALCOHOLIC HEPATITIS?	7
Validation of the Hepamet fibrosis score in a multi-ethnic Asian population	7
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination	7
Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients	7
Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis	7
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH	7
EDITORIAL BOARD	7
NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN THE POPULATION WITH TYPE 2 DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	7
Metabolic dysfunction: The silenced connection with fatty liver disease	7
Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis	7
Prevalence of hepatic encephalopathy in non-cirrhotic portal hypertension: A systematic review and meta-analysis	7
Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”	7
Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting	7
IMPORTANCE OF P450 POLYMORPHISM IN THE DEVELOPMENT OF DILI/HILI: HISTOLOGICAL AND BIOCHEMICAL FINDINGS	6
Different measures of sodium intake and the risk of metabolic dysfunction-associated steatotic liver disease: Evidence from the UK Biobank	6
P-121 SEPTIC SHOCK IN LIVER CIRRHOSIS: A COHORT STUDY OF A UNIVERSITY HOSPITAL IN CHILE	6
Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.	6
ARTIFICIAL INTELLIGENCE IN PREDICTING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE: DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL IN 306 PA	6
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease	6
Short-term response of p300 evoked potential in patients with minimal hepatic encephalopathy treated with l-ornithine, l-aspartate	6
Hepatocellular carcinoma and upper gastrointestinal bleeding	6
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	6
OP-5 ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) CRITERIA IN ALCOHOL-ASSOCIATED HEPATITIS: IMPLICATIONS FOR LIVER TRANSPLANTATION	6
Risk factors for sarcopenia in cirrhotic patients under evaluation for liver transplantation.	6

P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT	6
Hepatitis C virus NS5A and core proteins regulate epithelial-mesenchymal transition biomarkers in hepatoma cells	6
P- 54 HEPATITIS C MICROELIMINATION IN FORMER DRUG USERS	6
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for	6
P-75 INFLUENCE OF THE ARTERIAL HEPATIC FLOW IN ELASTOGRAPHY (2D SHEARWAVE) LIVER VALUES	6
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3	6
ELIMINATION OF HEPATITIS C AMONG HEMODIALYSIS PATIENTS IN ALAGOAS, BRAZIL	6
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria	6
Diethylnitrosamine and 2-acetylaminofluorene chronic administration leads to biochemical and histologic changes related to hepatocellular carcinoma in Wistar rats	6
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.	6
From NAFLD to MASLD: Promise and pitfalls of a new definition	5
P-77 TRIPLE THERAPY FOR DIFFICULT-TO-TREAT PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS	5
Colorimetric test for early diagnosis of spontaneous bacterial peritonitis.	5
P-7 EPIDEMIOLOGY OF AUTOIMMUNE HEPATITIS IN LATIN AMERICA: PRELIMINARY RESULTS FROM ALLATIN COHORT	5
Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review	5
The impact of early allograft dysfunction severity on graft and recipient outcomes in pediatric liver transplantation	5
Daytime napping and risk of liver cancer: A large population-based prospective cohort study	5
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.)	5
Sarcopenia in patients with liver cirrhosis according to hepatic functional reserve	5
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS	5
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients	5
Clinical spectrum and long-term outcomes of non-cirrhotic portal venous system thrombosis in Hispanic population	5
Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: a propensity-score matched-cohort study	5
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2	5
Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire	5
Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis	5
OP-13 CHOLANGIOCARCINOMA IN LATIN AMERICA: A MULTICENTER OBSERVATIONAL STUDY ALERTS ON ETHNICAL DISPARITIES IN TUMOR PRESENTATION AND OUTCOME	5
Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD	5
Editorial board	5
P- 73 ULTRASOUND VISUALIZATION OF THE LIVER	4
Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis	4
P- 39 N-ACETYL CYSTEINE ATTENUATES ALTERATIONS GENERATED IN EXPERIMENTAL LIVER STEATOSIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION PLUS A HYPERCALORIC DIET	4
A multinational survey of physician knowledge about management of chronic hepatitis C	4
O-37 AMOXICILLIN-CLAVULANATE INDUCED LIVER INJURY: TEN YEARS EXPERIENCE FROM LATINDILI REGISTRY.	4
LIVER FIBROSIS IN INDIVIDUALS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN LATIN AMERICA: INTERIM RESULTS FROM THE STELLA STUDY	4
PRIMARY BILIARY CHOLANGITIS AT A TERTIARY CARE HOSPITAL	4
P-121 CORRELATION BETWEEN HEPATOPULMONARY SYNDROME AND OXYGEN SATURATION PULSE OXIMETRY IN CIRRHOTIC PATIENTS	4
O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY	4
Evaluation of the ALBI, MELD, MELD-Na, MELD 3.0 score in patients with hepatocellular carcinoma treated with Yttrium-90 (90y)	4
Portal cholangiopathy secondary to cavernomatous transformation of the portal vein. Case report	4
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.	4
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C	4
HIGH PREVALENCE OF DILI/HILI IN A CENTER PARTICIPATING IN A MULTICENTER STUDY FOR DIAGNOSING ACUTE HEPATITIS IN BRAZIL	4
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial	4
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma	4
O-2 CHARACTERIZATION OF SERUM LEVELS OF BILE ACIDS, EXTRACELLULAR VESICLES AND ITS CARGO IN ALCOHOL-ASSOCIATED LIVER DISEASE	4
O-11 ENHANCEMENT OF F4/80+CD11B-CD206+ KUPFFER CELLS IN LIVER TISSUE: EFFECT OF MARESIN-1 AS HEPATOPROTECTIVE AGENT	4
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure	4
Evaluation of the hypolipidemic effect of cinnamon essential oil in a model of acute damage induced by triton WR-1339	4
Sarcopenia as a predictor of risk of minimal hepatic encephalopathy in patients with liver cirrhosis	4
FROM POLICY TO PRACTICE: HEPATITIS C CARE INDICATORS IN URUGUAY BEFORE AND AFTER THE INTRODUCTION OF PUBLIC HEALTH STRATEGIES	4
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States	4
P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLICAL HOSPITAL IN CHILE FROM 2015 TO 2022.	3
O-17 NUTRICIONAL AND PHYSICAL THERAPHY IMPROVES LIVER FRAILTY INDEX IN LISTED PATIENTS WITH CIRRHOSIS: RANDOMIZED CONTROLLED TRIAL. INTERIM ANALYSIS	3
P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER	3
Alcoholic cirrhosis-associated immune dysfunction: What does it imply for us?	3
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	3
MCM3 promotes hepatocellular carcinoma progression via Epithelial-mesenchymal Transition through AKT/Twist signaling pathway	3
MORTALITY TRENDS AND RISK FACTORS IN ALCOHOL-ASSOCIATED HEPATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	3
“Hepatocellular carcinoma surveillance: Current challenges in Latin America”	3
Liver fibrosis: More than meets the eye	3
P-85 IMPACT OF TECHNICAL NOTE No 32/2021 ON THE RATE OF LIVER TRANSPLANTS FOR REFRACTORY ASCITIS IN A TERTIARY HOSPITAL	3
P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS	3
Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value	3
Ethanol with thioacetamide murine model of alcoholic liver disease identifies hepatic pathways as targets for the human disease	3
Drug pricing for hepatitis B and C in Australia and Japan	3
Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018	3
O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C	3
O-20 EFFECTS OF ISOCALORIC AND NEGATIVE CALORIE BALANCE EXERCISE ON SERUM LEVELS OF INSULIN-LIKE GROWTH FACTOR TYPE 1 IN SUBJECTS WITH INITIAL AND ADVANCED FATTY LIVER	3
Response to: MAFLD treatment: emphasizing the concept of “homology of medicine and food”	3
Correlation of Cardiovascular Risk Score with Alterations in Carotid Intima-Media Thickness in Patients with MASLD	3
P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS	3
O-3 DEVELOPMENT OF LENTIVIRAL VECTORS FOR INHIBITION OF HEPATITIS B VIRUS VIA SMALL INTERFERING RNA	3
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?	3
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease	3
P- 48 EFFECT OF THE COMBINATION OF ORLISTAT AND L-CARNITINE ON THE QUALITY OF LIFE (SF.36) IN 16 OVERWEIGTH PATIENTS	3
P-27 DESCRIPTIVE STUDY ON PATIENTS WITH HEPATOCARCINOMA IN A PUBLIC HOSPITAL 2018-2023	3
A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues	3
Impact of bilirubin molecular species on mortality in patients with acute on chronic liver failure (ACLF).	3
P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.	3
The GDF11 represses the Stat3 signaling pathway, conferring metabolic, inflammatory, and oncogenic restrictions in cells derived from human hepatocellular carcinoma.	2
P- 101 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS IN TWO REFERENCE CENTERS IN PARAGUAY.	2
A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality	2
EXPERIENCE IN THE TREATMENT OF HEPATITIS C IN PREGNANT PATIENTS AT THE HEPATITIS CLINIC OF THE VERACRUZ HIGH SPECIALTY HOSPITAL	2
The role of the prognostic nutritional index as a prognostic factor in patients with hepatocellular carcinoma.	2
Prevalence of fibrosis and steatosis determined by transition elastography and controlled attenuation parameter (fibroscanâ) in diabetic patients	2
P- 103 PREVALENCE OF SARCOPENIA IN CIRRHOTIC PATIENTS IN AN OUTPATIENT SERVICE IN BRAZIL	2
P- 11 PROTUMORIGENIC GALECTINS 1 AND 3 ARE UPREGULATED IN THE LIVER OF MICE EXPOSED TO CONTINUOUS GROWTH HORMONE LEVELS	2
IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy	2
Simplification of the diagnostic approach and treatment of Hepatitis C Virus.	2
Evaluation of deubiquiyinase USP15 expression during HCV replication	2
Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?	2
A novel role of AIM2 inflammasome-mediated pyroptosis in radiofrequency ablation of hepatocellular carcinoma	2
Post-infantile giant cell hepatitis, management, six-year follow-up and re-transplantation, a successful case report during the pandemic	2
New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD	2